Granulomatosis with Polyangiitis: Difference between revisions

No edit summary
No edit summary
Line 140: Line 140:
add links to case studies here (case studies should be added on new pages using the [[Template:Case Study|case study template]])<br>
add links to case studies here (case studies should be added on new pages using the [[Template:Case Study|case study template]])<br>


== Resources <br> ==
== Resources <br> ==
 
1. &nbsp;National Institute of Allergy and Infectious Disease. &nbsp;Wegener's Granulomatosis. &nbsp;Available at:&nbsp;http://www.niaid.nih.gov/topics/wegeners/pages/symptoms.aspx. &nbsp;Accessed March 29, 2012.


<br>
<br>
2. &nbsp;Hoffman GS et al. &nbsp;Wegener granulomatosis: an analysis of 158 patients. ''&nbsp;Ann Intern Med''


== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==
== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==

Revision as of 21:21, 1 April 2012

Welcome to PT 635 Pathophysiology of Complex Patient Problems This is a wiki created by and for the students in the School of Physical Therapy at Bellarmine University in Louisville KY. Please do not edit unless you are involved in this project, but please come back in the near future to check out new information!!

Original Editors - Dalie Camic & Daryl Williams from Bellarmine University's Pathophysiology of Complex Patient Problems project.

Lead Editors - Your name will be added here if you are a lead editor on this page.  Read more.

Definition/Description[edit | edit source]

Wegener's granulomatosis is a rare disorder characterized by inflammation in the blood vessels, which in turn decreases blood flow to organs and systems.  Most affected areas include the kidneys, lungs, and upper respiratory tracts[1].

Prevalence[edit | edit source]

Wegener's granulomatosis is most common in middle aged adults, but has been seen in children as young as 3 months of age[1]. There is also increased incidence in caucasians versus African-American populations [2]

Characteristics/Clinical Presentation[edit | edit source]

The signs and symptoms of Wegener's Granulomatosis are not only common signs and symptoms of other diseases or illnesses but are often vague in the beginning presentations of this disease.  The first signs and symptoms include upper respiratory tract symptoms, joint pains, weakness, and tiredness.


Respiratory System

Common involvement occurs in the upper respiratory tract in nearly all patients.  

Symptoms include:  sinus pain, discolored or bloody fluid from nose, and nasal ulcers.  

Common signs include:  rhinorrhea ("runny nose"), common cold symptoms that do NOT respond to usual treatment and become increasingly worse.  Although this these are the most prevelant signs Wegener's Granulomatosis is rarely the cause.


Lungs:  Commonly affected in patients with Wegener's Granulomatosis there are rarely signs and symptoms that present.  Possible S&S can include cough, hemoptysis, shortness of breath, and chest discomfort.


Musculoskeletal system

Although it does not lead to permanent joint damage or deformities, pain in the muscle and joints, along with joint swelling affects two-thirds of individuals with this disease.


-Other signs and symptoms can include develop skin lesions resmembling red or purple raised lesions.  The eyes can be affected causing conjunctivitis, scleritis, episcleritis causing double vision, redness, burrning, and pain.  Symptoms involving the eyes require immediate medical attention.

Associated Co-morbidities[edit | edit source]

Ischemic heart disease [3]

Glucocorticoid-induced osteoporosis[4]

Medications
[edit | edit source]

In an article published in the Annals of Internal Medicine an analysis of 158 patients with Wegener Granulomatosis was prospectively studied to to analyze the clinical features, pathophysiology, treatment, and prognosis of the disease.


-138 Patients recieved "standard therapy" with daily low cyclophosphamide and glucocorticoids; 8 patients recieved only low-dose cyclophophamide; 6 patients were treated with other cytotoxic agents and glucocorticoids, and 10 patients were treated with only glucocorticoids.


- 91% percent of the patients experienced marked improvement, and 75% achieved complete remission.  


-The use of these medications shown a dramatic improvement by daily treatment with cyclophosphamide and glucocorticoids.  Alternative forms have not yet achieved the high rates of remission induction and maintaenece that have been reported with cyclophophamide treatment.  


-A major concern with the long term follow up of these patients is the toxicity resulting from prolonged cyclophosphamide therapy.


According pubmedhealth, treatment may include medicines that slow down the immune system response.  Some of these medications include:

-Gucocorticoids (Prednisone)

-Azathioprine

-Cyclophosphamide

-Methotrexate


These medications may be used in combination with other medications to help reduce side effects:

-Biphosphonate-to prevenent bone loss caused by prednisone.

-Folic acid

-Trimethoprim-to prevent lung infections.

Diagnostic Tests/Lab Tests/Lab Values[1][edit | edit source]

Blood panel

  • Antineutrophil cytoplasmic antibodies (ANCA) is a common protein found in patients with WG.

Urinalysis

  • Assess kidney function and check for output, blood or proteins in the urine

Biopsy is common and will vary depending on organ involvement. Can include:

  • lung
  • kidney
  • nasal mucosa
  • upper airway
  • skin

Other tests may be order to further evaluate the patient and confirm diagnosis:

  • chest x-ray
  • chest CT
  • bone marrow aspiration

Etiology/Causes[edit | edit source]

add text here

Systemic Involvement[edit | edit source]

add text here

Medical Management (current best evidence)[edit | edit source]

add text here

Physical Therapy Management (current best evidence)[edit | edit source]

add text here

Alternative/Holistic Management (current best evidence)[edit | edit source]

add text here

Differential Diagnosis[edit | edit source]

add text here

Case Reports/ Case Studies[edit | edit source]

add links to case studies here (case studies should be added on new pages using the case study template)

Resources
[edit | edit source]


Recent Related Research (from Pubmed)[edit | edit source]

see tutorial on Adding PubMed Feed

Failed to load RSS feed from http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1NGmwZeh8JwVIzrKgHG1LrDm0izTr7ViJiDkSYAY2BW5hiXsx0|charset=UTF-8|short|max=10: Error parsing XML for RSS

References[edit | edit source]

see adding references tutorial.

  1. 1.0 1.1 1.2 Wegener's Granulomatosis. Reviewed Feb 8, 2011; accessed March 29, 2012. Available from http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001192/
  2. Mayo Clinic Staff.Wegener's Granulomatosis. Updated Sept 25,2010. Accessed March 29, 2012. Available from mayoclinic.com/health/wegeners-granulomatosis
  3. Faurschou M, Mellemkjaer L, Sorensen IJ, Thomsen BS, Dreyer L, Baslund B. Increased morbidity from ischemic heart disease in patients with wegener's granulomatosis. Arthritis & Rheumatism. 2009 April;60(4):1187-1192
  4. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503